



PCT/IB 04 / 0 4 1 7 1

(1 6 . 1 2 . 0 4)

REC'D 16 DEC 2004

WIPO PCT

**WORLD INTELLECTUAL PROPERTY ORGANIZATION
ORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE**

34, chemin des Colombettes, Case postale 18, CH-1211 Genève 20 (Suisse)
Téléphone: (41 22) 338 91 11 - e-mail: wipo.mail @ wipo.int. - Fac-similé: (41 22) 733 54 28

**PATENT COOPERATION TREATY (PCT)
TRAITÉ DE COOPÉRATION EN MATIÈRE DE BREVETS (PCT)**

**CERTIFIED COPY OF THE INTERNATIONAL APPLICATION AS FILED
AND OF ANY CORRECTIONS THERETO**

**COPIE CERTIFIÉE CONFORME DE LA DEMANDE INTERNATIONALE, TELLE QU'ELLE
A ÉTÉ DÉPOSÉE, AINSI QUE DE TOUTES CORRECTIONS Y RELATIVES**

International Application No. } PCT/IB 0 3 / 0 6 0 1 6.
Demande internationale n° }


International Filing Date } 1 6 DECEMBER 2003
Date du dépôt international }
(1 6 . 1 2 . 0 3)

Geneva/Genève, 1 9 JANUARY 2005
(1 9 . 0 1 . 0 5)

**International Bureau of the
World Intellectual Property Organization (WIPO)**

**Bureau International de l'Organisation Mondiale
de la Propriété Intellectuelle (OMPI)**

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



J.-L. Baron

Head, PCT Receiving Office Section
Chef de la section "office récepteur du PCT"

REQUETE PCT

Original (pour PRESENTATION) - imprimé le 16.12.2003 05:49:28 PM

0	Réservé à l'office récepteur	
0-1	Demande Internationale No.	PCT/IB 03 / 0 6 0 16
0-2	Date du dépôt international	16 DECEMBER 2003
0-3	Nom de l'office récepteur et "Demande internationale PCT"	INTERNATIONAL BUREAU OF WIPO PCT International Application
0-4	Formulaire - PCT/RO/101 Requête PCT	
0-4-1	Préparé avec	PCT-EASY Version 2.92 (mis à jour 01.11.2003)
0-5	Pétition Le soussigné requiert que la présente demande internationale soit traitée conformément au Traité de coopération en matière de brevets	
0-6	Office récepteur (choisi par le déposant)	Bureau international de l'Organisation Mondiale de la Propriété Intellectuelle (RO/IB)
0-7	Référence du dossier du déposant ou du mandataire	BR76008/DC1
I	Titre de l'invention	METHODS AND COMPOSITIONS FOR ASSAYING MUTATIONS IN NUCLEIC ACIDS
II	Déposant	
II-1	Cette personne est :	Déposant seulement
II-2	Déposant pour	Tous les Etats désignés sauf US
II-4	Nom	INSTITUT CURIE
II-5	Adresse:	26 rue d'Ulm F-75248 CEDEX 05 PARIS France
II-6	Nationalité (nom de l'Etat)	FR
II-7	Résidence (nom de l'Etat)	FR
III-1	Déposant et/ou inventeur	
III-1-1	Cette personne est :	Déposant seulement
III-1-2	Déposant pour	Tous les Etats désignés sauf US
III-1-4	Nom	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
III-1-5	Adresse:	3 rue Michel Ange F-75794 CEDEX 16 PARIS France
III-1-6	Nationalité (nom de l'Etat)	FR
III-1-7	Résidence (nom de l'Etat)	FR

REQUETE PCT

2/4

PCT/IB 03 / 06016

BR76008/DC1

Original (pour PRESENTATION) - imprimé le 16.12.2003 05:49:28 PM

III-2	Déposant et/ou inventeur	
III-2-1	Cette personne est :	Déposant et inventeur
III-2-2	Déposant pour	US seulement
III-2-4	Nom (NOM DE FAMILLE, Prénom)	VIOVY, Jean-Louis
III-2-5	Adresse:	26 rue de l'Espérance F-75013 PARIS France
III-2-6	Nationalité (nom de l'Etat)	FR
III-2-7	Résidence (nom de l'Etat)	FR
IV-1	Mandataire ; Représentant commun ou adresse pour la correspondance. La personne nommée ci-dessous est/ a été désignée pour agir au nom du ou des déposants auprès des autorités internationales compétentes, comme	mandataire
IV-1-1	Nom	NONY & ASSOCIES
IV-1-2	Adresse:	3 rue de Penthièvre F-75008 PARIS France
IV-1-3	No. de téléphone	(33)1 43 12 84 60
IV-1-4	No de télécopieur:	(33)1 43 12 84 70
IV-1-5	Courrier électronique:	nony@nony.fr
V	Désignation d'Etats	
V-1	Brevet régional (d'autres formes de protection ou de traitement, le cas échéant, sont spécifiées entre parenthèses pour les Etats désignés concernés)	AP: BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW et tout autre Etat qui est un Etat contractant du Protocole de Harare et du PCT EA: AM AZ BY KG KZ MD RU TJ TM et tout autre Etat qui est un Etat contractant de la Convention sur le brevet eurasien et du PCT EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR et tout autre Etat qui est un Etat contractant de la Convention sur le brevet européen et du PCT OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG et tout autre Etat qui est un Etat membre de l'OAPI et un Etat contractant du PCT

REQUETE PCT

BR76008/DC1

Original (pour PRESENTATION) - imprimé le 16.12.2003 05:49:28 PM

V-2	Brevet national (d'autres formes de protection ou de traitement, le cas échéant, sont spécifiées entre parenthèses pour les Etats désignés concernés)	AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW	
V-5	Déclaration concernant les désignations de précaution Outre les désignations faites sous les rubriques V-1, V-2 et V-3, le déposant fait aussi, conformément à la règle 4.9.b), toutes les désignations qui seraient autorisées en vertu du PCT, à l'exception de toute désignation(s) indiquée(s) dans la rubrique V-6 ci-dessous. Le déposant déclare que ces désignations additionnelles sont faites sous réserve de confirmation et que toute désignation qui n'est pas confirmée avant l'expiration d'un délai de 15 mois à compter de la date de priorité sera considérée comme retirée par le déposant à l'expiration de ce délai.		
V-6	Exclusion(s) des désignations de précaution	NEANT	
VI	Revendication de priorité	NEANT	
VII-1	Administration chargée de la recherche internationale choisie	Office européen des brevets (OEB) (ISA/EP)	
VIII	Déclarations	Nombre de déclarations	
VIII-1	Déclaration relative à l'identité de l'inventeur	-	
VIII-2	Déclaration relative au droit du déposant, à la date du dépôt international, de demander et d'obtenir un brevet	-	
VIII-3	Déclaration relative au droit du déposant, à la date du dépôt international, de revendiquer la priorité de la demande antérieure	-	
VIII-4	Déclaration relative à la qualité d'inventeur (seulement aux fins de la désignation des États-Unis d'Amérique)	-	
VIII-5	Déclaration relative à des divulgations non opposables ou à des exceptions au défaut de nouveauté	-	
IX	Bordereau	Nombre de feuilles	
IX-1	Requête (y compris les feuilles pour déclaration)	4	Dossier(s) électronique(s) joint(s)
IX-2	Description	32	-
IX-3	Revendications	4	-
IX-4	Abrégé	1	EZABST00.TXT
IX-5	Dessins	7	-
IX-7	TOTAL	48	

REQUETE PCT

BR76008/DC1

Original (pour PRESENTATION) - imprimé le 16.12.2003 05:49:28 PM

	Eléments joints	Document(s) papier joint(s)	Dossier(s) électronique(s) joint(s)
IX-8	Feuille de calcul des taxes	✓	-
IX-17	Disquette PCT-EASY	-	Disquette
IX-19	Figure des dessins qui doit accompagner l'abrégé		
IX-20	Langue de dépôt de la demande internationale	anglais	
X-1	Signature du déposant, du mandataire ou du représentant commun		
X-1-1	Nom	NONY & ASSOCIES Pascale LE COUPANEC Mandataire	
X-1-2	Nom du signataire		
X-1-3	Qualité		

RESERVE A L'OFFICE RECEPTEUR

10-1	Date effective de réception des pièces supposées constituer la demande internationale	16 DECEMBER 2003 (16.12.03)
10-2	Dessins:	
10-2-1	Reçus	
10-2-2	non reçus	
10-3	Date effective de réception, rectifiée en raison de la réception ultérieure, mais dans les délais, de documents ou de dessins complétant ce qui est supposé constituer la demande internationale:	
10-4	Date de réception, dans les délais, des corrections demandées selon l'article 11.2) du PCT	
10-5	Administration chargée de la recherche internationale	ISA/EP
10-6	Transmission de la copie de recherche différée jusqu'au paiement de la taxe de recherche	

RESERVE AU BUREAU INTERNATIONAL

11-1	Date de réception de l'exemplaire original par le Bureau international	
------	--	--

Methods and compositions for assaying mutations in nucleic acids

The present invention concerns improved methods for assaying mutation(s) in nucleic acids, in particular point mutation in nucleic acid in duplex form.

Recent developments in genomics have raised considerable hopes for improvements in human health and biotechnology.

In medicine, for instance, the understanding and diagnosis of genetic diseases and cancers, or the study of infectious organisms, rely more and more on analysis of DNA and nucleic acids.

Biotechnology is also more and more dependent upon molecular genetic and nucleic acids high throughput analysis. In particular, mapping of genetic differences between individuals is of growing importance for forensic investigations, medical applications, biotechnology and food industry.

For example, detecting mutations leading to abnormal proteins can be essential for identifying the genetic origin of a disease. A number of inherited pathological conditions may be diagnosed before onset of symptoms, using methods for structural analyses of DNA. In cancer research, for example, the search of mutations in BRCA1 and BRCA2 genes, recognized to lead to strong increase in breast cancer, is now performed on a large scale. The gene APC is also known to lead to strong predisposition to colorectal cancer. Genetic screening can also be performed at an early age, or even *in utero*, for numerous heritable diseases. At present, 700 genetic diseases have been identified among which thalassemia or myopathy.

The identification and detailed analysis of acquired genetic disorders, such as arising in particular in cancer, is also raising the hopes of more efficient and personalized treatments, by means of "genetic mapping" of tumors. Large scale genetic screening of mutations and genetic variability, also called "genotyping", is also of paramount importance for determining correlations between diseases and genes, in order to find new targets for therapy, in a pharmacogenomic approach.

Genetic screening can also be used for detecting pathogens, including identification of specific pathogenic varieties in medicine, food industry, veterinary or bioterrorism applications. For example, in food industry, the detection of genetically modified organism "GMO" in starting material or foodstuff is an increasing concern.

A need exists, therefore for a methodology to detect mutations in a DNA fragment relative to the wild type in an accurate, reproducible and reliable manner.

DNA molecules are linear polymers of subunits called nucleotides. Each nucleotide comprises a common cyclic sugar molecule, which is linked by phosphate group to the sugar of the adjoining nucleotide, and one of the different cyclic substituents called bases. The combination of the phosphate and base is called a nucleoside. The four bases commonly found in DNAs from natural sources are adenine, guanine, cytosine and thymidine, hereinafter referred to as A, G, C and T, respectively. The linear sequence of these bases in the DNA of an individual is its "genome". It involves coding regions, which bear the information for synthesis of proteins, regions for regulation of gene expression, and so called "non-coding" regions, the role of which being not fully understood.

In double-stranded DNA, the form adopted by DNA in the chromosomes of all cellular organisms, the two DNA strands are entwined in a precise helical configuration with the bases oriented inward, allowing interactions between bases from opposing strands. The two strands are held together in precise alignment mainly by hydrogen bonds which are permitted between bases by a complementarity of structures of specific pairs of bases. This structural complementarity is determined by the chemical natures and locations of substituents on each of the bases, leading in particular to a definite number and orientation of hydrogen bonds. Thus, in double-stranded DNA, normally each A on one strand has an attractive interaction with a T from the opposing strand, involving two hydrogen bonds, and each G has an attractive interaction with an opposing C involving three hydrogen bonds. In principle, they insure that DNA molecules are replicated and precise copies are passed on to the cell descendants during cell reproduction (mitosis), or to the offspring of the individual, when replication concerns the gametes (meiosis).

Occasionally, an incorrect base pairing does occur during replication, which, after further replication of the new strand, results in a double-stranded DNA offspring with a sequence containing a heritable single base difference from that of the parent DNA molecule. Such heritable changes are called genetic mutations, or more particularly in the present case, "point mutations". Mapping of genetic mutations involves both the detection of sequence differences between DNA molecules comprising substantially identical (i.e., homologous) base sequences, and also the physical localization of those differences within some subset of the sequences in the molecules being compared. Variations in the DNA

sequence may also affect non-coding regions. In particular, highly variable such as short tandem repeats (STR) or Single nucleotide polymorphism (SNP), exist in non-coding regions, and are very useful in genotyping.

5 Detecting point mutations, and in particular substitutions, is particularly challenging, because they are very localized, and in many occurrences their position cannot be known in advance. Actually, for many mutations associated with diseases, the exact location of the mutation is not known a priori, and the whole coding sequence of the gene (generally representing several thousands or tens of thousands of bases) must be screened completely.

10 The most prominent technologies at present for nucleic analysis are capillary electrophoresis and hybridization arrays, also called "DNA or RNA chips". The two techniques are rather complementary: Hybridization methods are well adapted to ultra-high throughput and semi-quantitative evaluations on small sequences, whereas electrophoresis remains unchallenged for high resolution, for reproducibility and for the analysis of large
15 molecules or fragments. Other systems, called "laboratories-on-chips" or "microfluidic systems", are also under development, and bear the promise of simpler, more cost-effective and more high-throughput analyses in the analysis of nucleic acids.

If the position of the mutation is known, one mostly uses single nucleotide primer extension, hybridization arrays, or quantitative PCR.

20 In single nucleotide primer extension, a sequencing reaction is performed, in conditions in which extension from the primer can start only if a given base (A,T,G, or C) follows the primer. The same reaction is performed for each base, and detection of extension is performed by a conventional sequencing electrophoresis.

In hybridization arrays, different "probe" DNA fragments or oligonucleotides
25 encompassing the point mutation, and bearing all expected mutations, are arranged in an array on the surface of a "chip", and put in presence of the target nucleic acid to test (DNA or RNA). With suitable hybridization conditions, it is expected that the target will hybridize only with the probe bearing the exactly complementary sequence, thus identifying the sequence of the target. The main difficulty with this approach, is that the
30 hybridization energy difference between the mutated and the normal (wild type) probe can be rather low, especially in the case of substitutions. It is thus difficult to find optimal conditions to get "yes or no" answers, and the difference in signal can be rather faint. This

difficulty, combined with the relatively low reproducibility of hybridization arrays, leads to a significant error rate. In addition, the hybridization free energy depends rather strongly on the sequence. It is for instance, higher for sequences with a high GC content. Thus, a duplex with a high GC content and a mismatch, may have an affinity actually higher than a perfect duplex with the same length, but a low GC content. It is thus very difficult, if not impossible, to achieve a unique set of hybridization conditions (temperature and buffer) for testing in parallel many different sequences in a single array.

Various approaches have been proposed to improve the selectivity between matched and mismatched pairs in hybridization arrays. In Maskos et al., *Nucleic Acids Research*, 21, 4663-4669, 1993, for instance, the effort was applied to the choice of stringency of the buffer, but only with limited success. In Chiari et al., (HPCE 2003, San Diego, CA, Jan 17-22, 2003) a hybridization method is proposed, in which DNA probes are replaced by peptide nucleic acids (PNA). PNA are nucleic acids homologs, presenting a peptide (instead of phosphate) backbone. The hybridization energy per base pair is higher in a PNA/DNA pair than in an equivalent DNA/DNA pair, because the PNA backbone is neutral, so that electric repulsion is suppressed. It also appears that the use of PNA allows the use of shorter oligonucleotides, thus increasing the association energy difference between matched and mismatched pair, in the case of point mutations. PNAs, however, are very expensive, and the main strategies for constructing high density arrays are not transposable to the PNA chemistry. In WO 00/56916, Mogens et al. describe the use of another class of DNA analogs, locked nucleic acids (LNA). LNAs are nucleic acids in which the backbone is bi-cyclic. LNAs have a stronger affinity to complementary DNA than natural DNA, and also exhibit higher selectivity versus mismatches. However, the difficulties raised by PNA, such as cost and difficulties to make high density arrays are also present for LNA.

In fact, primer extension or hybridisation methods appear to be not well adapted to the search of mutations which position on the genome is not known.

Accordingly, prior and important efforts have been exerted in order to find efficient, fast and inexpensive methods for the detection of point mutation by capillary electrophoresis. (for review, see e.g. Righetti, P.G., Gelfi, C., in "Analysis of Nucleic Acids by Capillary Electrophoresis, Heller, C, Ed., Chromatographia CE series, Vol

1Vieweg press, 1997, 255-271.). The major techniques presently available are termed
"Direct sequencing" and "Single Strand Conformation Polymorphism (SSCP)".

5 In the approach "Direct sequencing" the whole gene is sequenced totally for
each patient, a powerful but costly method. In addition, due to the presence of
heterozygothy, mutated patient sequences are not « pure », and the interpretation of data is
not as straightforward as for conventional sequencing. Most importantly, this method is
long and costly, since the whole gene and the flanking regions must be entirely sequenced
for each patient or individual to screen.

10 In the approach, "Single Strand Conformation Polymorphism" (SSCP) which
has been extensively used because of its simplicity, double-stranded DNA is denatured,
and then renatured rapidly in conditions such that each single strand collapsed on itself.
The mobility differences between the native and the mutated strands are then analysed by
electrophoresis. Unfortunately, the mobility difference can vary a lot depending on the
specific sequence of the DNA, and on the position of the mutation. For instance, a
15 mutation driving DNA folding into a different path will lead to a strong difference in
mobility, whereas a mutation, e.g. at the tip of a loop, will lead to essentially no change.
This lack of consistency in the sensitivity makes this technique not very attractive for
diagnosis, since it yields a relatively high number of false negatives. In WO 00/20853, an
improved SSCP method is proposed, in which several SSCP separations with selected
20 conditions are performed on each sample. Sensitivity is significantly improved, but the
duration and complexity of the analysis is also increased considerably.

At last, it is noticed that a series of other mutation detection methods is based
on the formation or dissociation of heteroduplexes.

25 A heteroduplex as opposed to a homoduplex is a double stranded DNA which
base sequence of one strand is not entirely complementary to the base sequence of the
other strand. In other words, it contains at least one base pair which is not complementary,
also termed "a mismatch". A heteroduplex can be formed during DNA replication when an
error is made by a DNA polymerase enzyme and a non-complementary base is added to a
polynucleotide chain being replicated. A heteroduplex can also be formed during repair of
30 a DNA lesion. Further replications of a heteroduplex will, ideally, produce homoduplexes

which are heterozygous, i.e. these homoduplexes will have an altered sequence compared to the original parent DNA strand.

5 A majority of genetic diseases or genetic predisposition to diseases are such that affected persons have precisely for the involved gene one normal copy and one mutated copy. When a DNA fragment including the location of the gene is amplified by PCR, both genes are amplified. When the amplified DNA is denatured and then renatured slowly, 4 different types of duplex DNA are obtained, i.e.: two homoduplexes, corresponding to the DNA of the two initial alleles (the normal one and the mutated one), and two heteroduplexes, mixing one strand from one allele and the (almost) 10 complementary strand from the other allele. These heteroduplexes contain, at the location of the mutation, a mismatch "bubble". These mismatches "bubbles" are generally searched by one of the following techniques:

In the method termed "Denaturing Gradient Gel Electrophoresis (DGGE)", duplex DNA are separated in a gel containing a gradient of denaturing conditions, so that 15 they will melt during electrophoresis. Since the mobility of duplex and melted DNA is different, this method is very sensitive to the exact position of the melting. Heteroduplexes tend to melt faster than the corresponding homoduplexes, and can be distinguished this way. Various variants of this technique, in gel or capillary format, have been proposed, and some achieve high sensitivity. However, duplexes with different base pair contents melt at 20 different temperatures, so that for each fragment the gradient range must be accurately adjusted. In addition, the preparation of the gradient gels is itself quite demanding and labor-intensive, so that the use of this technique for diagnosis or large scale screening is impractical.

Others techniques based on enzymatic or chemical cleavage, by e.g. cleavase, 25 T4 endonuclease, or Osmium Tetroxyde, were also proposed. The principle of enzymatic cleavage, described e.g. in US1996/0714626 is to obtain cleavage specifically at the point of mismatch, and to analyse *in fine* the size of the fragments. High sensitivities were reported, but this technique implies extra chemical steps and, as for SSCP, the reaction is sequence dependent. A related method, described in US1994/0334612, involves 30 recognition of the mutation by specific proteins, and analysing the resulting DNA-protein complex. This method, too, involves expensive enzymes, and the protocol is quite complex.

A third method, termed "chromatography in a gradient of denaturing conditions" (DHPLC) obeys to a principle relatively similar to that of DGGE, but the gradient of denaturing conditions is temporal, and can be automated on a HPLC apparatus. The renaturated (homoduplexes and, when relevant, heteroduplexes) DNA are adsorbed on a HPLC column, and the denaturation of DNA (which occurs slightly earlier for heteroduplexes) leads to the release of the DNA, and to detection at the output of the column. (see e.g. Wagner, T., Stoppa-Lyonnet, D., Fleischmann, E., Muhr, D., Pages, S., Sandberg, T., Caux, V., Moeslinger, R., Langbauer, G., Borg, A., Oefner, P., Genomics, 1999, 62, 369-376). However, the whole process of DHPLC is long when large genes have to be screened, because of the sequential nature of HPLC, which can analyse only one sample at a time.

An improvement of the DHPLC method is proposed in WO03/031580. This invention concerns a chromatographic method for separating heteroduplex and homoduplex DNA molecules in a test mixture. In one embodiment, the method includes: (a) applying the test mixture to a reverse phase separation medium; (b) eluting the medium of step (a) with a mobile phase comprising at least one nitrogen-containing mobile phase additive, wherein the eluting is carried out under conditions effective to at least partially denature the heteroduplexes and wherein the eluting results in the separation, or at least partial separation, of the heteroduplexes from the homoduplexes. The eluting is preferably carried out at a pre-selected concentration of the additive and at a pre-selected temperature. Examples of a preferred nitrogen-containing additive include betaine, tetra methyl ammonium chloride, tetraethylammonium chloride, triethylamine hydrochloride, and choline. This improvement increases the sensitivity of DHPLC for point mutations difficult to detect, such as A/T substitutions, but it does not improve on the speed of separation, nor relieves the tedious requirement of having to adapt the denaturing gradient for each fragment to analyze.

Another method, termed "Electrophoretic Heteroduplex Analysis", (EHDA) directly measures, by electrophoresis in non-denaturing conditions, the difference in mobility induced by a « denaturation bubble » or « loop » associated with the mismatch appearing in heteroduplex pairs. When the sample is separated by electrophoresis in non-denaturing conditions, the presence of a local "mismatch bubble" on the heteroduplex molecules leads to a difference in geometry of flexibility of the double strand, which leads

to a difference in mobility, as compared to the homoduplexes. If the DNA to analyse presents a normal duplex fragment and a mutated fragment (i.e. if the organism from which the DNA is extracted is heterozygote for the corresponding DNA fragment), a multiplicity of peaks (two to four) will appear in the electrophoregram. The power of the EHDA method relies mainly on the ability to detect the slight difference in migration velocity, due to the presence of mismatch bubble. This technique is simple, and fast, but up to now its detection sensitivity was weaker than that of DGGE or DHPLC, and was not considered suitable for diagnosis.

Improvement to this method has consisted to use additives such as urea, known to lower the melting point of duplex nucleic acids and increase the size of denaturation bubbles. However, such additives actually lead to a decrease in the resolution of mismatches as illustrated in the following example 5.

Another kind of improvement to EHDA involves the use of a liquid separating medium comprising block copolymer(s) with an acrylamide backbone and PDMA side-chains for electrophoretic separation of homoduplexes and heteroduplexes. The PDMA block, rather hydrophobic, is used to attach the polymer to the wall, and the backbone, hydrophilic, extends in the buffer like a "brush" and repels other macromolecules (Barbier, Fr. Pat. Appl. 00/08526 included here by reference). This allows a better resolution than conventional EHDA, and a sensitivity to mutations comparable to DHPLC. In addition, this method can be implemented in capillary array electrophoresis, thus leading to high throughput. However, in spite of this improvement, not all mutations can be detected, and further improvements are necessary.

At last, US 2002/0055109 discloses a method of isolation of heteroduplexes containing at least one internal single stranded region with a single-strand binding protein. The single-strand binding protein having a preferential affinity for single stranded DNA compared to double stranded DNA is selected from the *E. coli* SSB, the product of gene 32 of phage T4, the adenovirus DBP and the calf thymus UP1. However, such a method is not suitable to detect very local mutations, such as those relative to a single base mismatch, or to an insertion or deletion of only one nucleotide or a very small number of nucleotides.

Accordingly, there is still a need for a simple and very specific method for directly detecting at least one single base difference in nucleic acids such as genomic DNA

in which detection steps are minimized resulting in a method which may be performed quickly, accurately and easily with minimal operator skills.

It is precisely an object of the invention, to provide new methods for improving the detection of mutations, in particular unknown mutations, in nucleic acids.

5 In one of its aspects, the invention concerns a method for assaying the presence or the absence of at least one mutation on a strand of nucleic acids paired in a duplex form comprising at least the steps consisting of:

- contacting in a liquid medium said duplex, suspected to include at least one mismatch, with at least one compound able to undergo a specific base pairing

10 interaction with said mismatch, said compound being at a concentration of at least 1g/l of said medium and,

- assaying for said mismatch by an analytical method.

The strands of nucleic acid paired in a duplex form are two DNA strands which are in all or in part complementary.

15 According to one embodiment, the method of the invention involves the use of an electrophoretic analysis as an analytical method.

According to another embodiment, the method of the invention involves the use of hybridization arrays, like DNA chips for example, as an analytical method.

20 The instant invention concerns, according to another aspect, a method for performing Electrophoretic Heteroduplex Analysis "EHDA" on a nucleic acid sample suspected to include at least one heteroduplex said method comprising at least the steps consisting of:

- contacting in a liquid medium said nucleic acid sample suspected to include at least one heteroduplex, with at least one compound able to undergo a specific

25 base pairing interaction with at least one mismatch of said heteroduplex, said compound being at a concentration of at least 1g/l of said medium,

- assaying for the presence of said heteroduplex thanks to its electrophoretic mobility.

30 In the case where the nucleic acid sample initially includes homologous strands corresponding to different alleles, the method according to the invention comprises a preliminary step of denaturing the nucleic acid sample and renaturing it in conditions convenient to achieve both heteroduplexes and homoduplexes.

In another aspect, the invention concerns a method for assaying the presence or the absence of at least one mutation on a single strand of nucleic acid in a liquid medium and comprising at least the steps consisting of:

- a) contacting said nucleic acid suspected to include at least one mutation with at least a nucleic acid probe grafted on a solid support,
 - b) allowing the hybridization of at least a part of said strand of nucleic acid with the grafted nucleic acid probe,
 - c) washing non-hybridized strands, and
 - d) assaying for said mutation by an analytical method,
- wherein the steps a) and/or c) are performed in the presence of at least one compound able to undergo a specific base pairing interaction with a mismatch, said compound(s) being at a concentration of at least 1g/l.

The methods according to the invention are particularly useful for either the diagnosis of the predisposition to diseases associated or putatively associated to specific point mutation(s) or the diagnosis or prognosis of such disease(s).

Accordingly, the instant invention further relates to their uses in the diagnosis of predisposition to genetic diseases or cancers or the diagnosis or prognosis of said diseases or cancers.

The invention also relates to the use of said methods in therapy of said diseases.

In particular, concerned diseases may include many cancers as soon as they are associated or putatively associated to specific point mutation(s) such as melanoma, ocular melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, multiple myeloma, sarcoma, myosarcoma, cholangiocarcinoma, squamous cell carcinoma, and cancers of the pancreas, breast, brain, prostate, bladder, thyroid, ovary, uterus, testis, kidney, stomach, colon and rectum.

According to another aspect, the instant invention concerns a method for assaying a nucleic acid for mutation comprising at least the steps consisting in:

- performing a polymerase chain reaction on said nucleic acid in the presence of at least two primers and a pool of compounds able to undergo specific base

pairing interaction with nucleotides or analog thereof, said compounds being at a combined concentration of at least 1 g/l and being unable to interfere with the polymerase chain reaction and,

- analyzing and/or quantifying the so-obtained DNA fragments.

5

According to another aspect, the present invention provides a composition including at least a compound able to undergo specific base pairing interaction at a concentration of at least 1g/l, and a pair of molecules or groups acting as a DNA probe called "molecular beacon", wherein said compound is as defined according to the invention.

10

In a preferred embodiment, at least one of the molecules or groups involved in the molecular beacon pair is associated with a nucleic acid or nucleic acid analog.

According to another aspect, the present invention also provides a composition including at least a compound able to undergo specific base pairing interaction at a concentration of at least 1g/l and at least a polymer compound said polymer being as defined according to the invention.

15

In particular, the present invention is also directed to a kit useful for the screening of a nucleic acid or analog thereof having a nucleic sequence related to a gene on which point mutation(s) has been associated or putatively associated with a disease or an increased predisposition to a disease, said kit comprising at least a composition as defined previously i.e. including at least a compound able to undergo specific base pairing interaction at a concentration of at least 1g/l and a polymer, as defined according to the invention.

20

In particular, the kits according to the invention are particularly useful for the screening of the human breast cancer predisposing genes, (BRCA) like BRCA1 and BRCA2, for mutations.

25

According to another aspect, the present invention also provides a composition including at least a DNA fragment having a nucleic sequence related to a gene on which point mutations have been associated or putatively associated with a disease or an

30

increased predisposition to a disease, and at least a compound able to undergo specific base pairing interaction at a concentration of at least 1 g/l.

5 In particular, such a composition may include at least a DNA fragment having a nucleic sequence related to a human breast cancer predisposition gene (BRCA) and at least a compound able to undergo specific base pairing interaction at a concentration of at least 1 g/l.

10 COMPOUNDS ABLE TO UNDERGO SPECIFIC BASE PAIRING INTERACTIONS

According to the invention, "compound able to undergo specific base pairing interaction" in particular with a nucleotide involved in a mismatch, includes any compound presenting at least two groups suitable for hydrogen bonding, in an orientation, polarity and spacing compatible with the creation of attractive interactions with at least one of the
15 "bases" A, T, G, U or C.

According to the invention a compound able to undergo specific base pairing interaction with said mismatch is in particular a compound able to undergo a specific base pairing interaction with the nucleotides formed with the bases A, T, G, C, U.

20 In others words, the compounds considered according to the invention, are capable of exhibiting an interaction specifically directed towards at least one specific base. For example, some compounds may exhibit a specific base pairing interaction for adenine, and other compounds for cytosine.

A compound, according to the invention, may be used alone or in mixture with one or several other compounds able to undergo specific base pairing interactions with the
25 base(s) of the nucleic acid(s) involved in the mismatch of a heteroduplex.

In a preferred embodiment, the compounds are chosen such as they cannot be incorporated into the enzymatic polymerisation of a nucleic acid, such as performed e.g. by the action of a polymerase on a single-strand template. Accordingly, said compound is
30 unable to interfere with polymerisation reactions of nucleotides and/or to be incorporated into a newly polymerized DNA strand. By this way, said compounds are only able to

enhance the detection of mutations but not prone to interfere significantly with polymerisation reactions.

The mechanism of action of the compounds considered according to the invention is very unexpected compared to that of known additives.

5 An interpretation of this beneficial effect, is that by performing base-pairing interactions with the denaturation bubble, the compounds of the invention stabilize the mismatch bubble, and thus increase the difference in geometry between heteroduplexes and homoduplexes. This interaction is sufficiently efficient for leading to a difference of behaviour of the heteroduplexes compared to the homoduplexes in an analytical method.

10 Where the analytical method is an electrophoretic method, the mobility of heteroduplexes is modified compared to homoduplexes and allows, by this way, to distinguish ones from the others. Both compounds will not have the same retention time or affinity.

 Where the analytical method is a hybridization method, the induced effect is a
15 decrease of the stability of heteroduplexes compared to homoduplexes. This difference of stability is particularly sensitive for minor mismatches, such as those resulting from substitutions, which are the most difficult mutations to detect in hybridization arrays. According to this specific embodiment, the compound(s) of the invention may be present during the hybridization and more specifically in the hybridization medium and/or during
20 the washing step and in particular in the washing solution used for cleaning the non-hybridized strands.

 Compounds interacting non-specifically with nucleic acids, such as urea or other denaturants or chaotropic solvents, also increase the probability of denaturation bubbles, but thus very likely do it also at different places along the double helix not
25 corresponding to the mismatch, this broadening the peak in the case of electrophoretic analysis and altering the resulting separation.

 In the case of the instant invention, the increase in mismatch resolution is in contrast particularly significant with compounds able to undergo specific base pairing interactions with nucleotides. Very surprisingly, though, this effect is interesting mostly
30 with compounds presenting a very limited number of base-pairing interactions (one base pairing interaction per compound is sufficient), whereas methods for mutation detection in the prior art, such as single-nucleotide primer extension, used "primers" able to achieve

base pairing interactions with numerous, typically at least 12 base pairing interactions per molecule.

Another unexpected feature of the invention, is that the compounds able of specific base pairing interactions with the nucleic acids to be tested, are used with best performances at much higher concentrations, as generally used for base-pairing compounds in the prior art.

In particular said compounds are used at a combined concentration of at least 1 g/l of the liquid medium used for contacting it or them with the nucleic acid to assay for mutation, preferably at least 10 g/l and most preferably at least 25 g/l.

By "combined concentration", it is understood the total concentration of said compounds, e.g. in the case of the use of several types of compounds, the combined concentration is the total of the concentrations of each compound.

The concentration of compound(s) according to the instant invention is expressed with respect to the total volume of the medium containing the nucleic acid to analyze.

In one embodiment of the present invention, said compounds are different from antibody.

In another embodiment, said compounds are different from enzymes.

In another embodiment, they are different from proteins.

According to a preferred embodiment, such a compound is selected in the group consisting of an oligonucleotide having a length of less than 5 nucleotides, preferably less than 3 nucleotides and more preferably less than 2 nucleotides, a nucleoside, a base or a mixture thereof.

Non restrictive examples of such compounds are:

- the bases adenine (A), guanine (G), cytosine (C), uracile (U) and thymine (T),
- adenine, guanine, cytosine, uracile and thymine bearing various substitutions, and in particular substitutions having none effect on the amino and OH groups responsible for base pairing interactions in unsubstituted bases,
- the nucleosides formed with the bases A, T, G, C, U,
- the nucleotides formed with the bases A, T, G, C, U,
- oligonucleotide analogs, and variously substituted oligonucleotides.

In numerous preferred applications, said compounds contain one single base-pairing-unit, with "base pairing unit" meaning a molecular group able to undergo one base pairing interaction with one of the bases, A, T, G, U or C.

5 The term "nucleotide", "oligonucleotide" or "nucleoside" is also used herein to refer to individual species or varieties of species, meaning a compound, comprising a purine or pyrimidine moiety, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide.

10 The term "nucleotide", "oligonucleotides" and "nucleoside" is also used herein to encompass "modified species" which comprise at least one modification such as (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar.

15 The term "nucleotide", "oligonucleotides" and "nucleoside" is also used herein to encompass "substituted species" which comprise at least one substituant chosen to increase their solubility, change their charge, or modify their friction in a solvent. For example, it may be nucleotides or nucleosides bearing a polymeric or oligomeric, hydrophilic substituant and/or a charge.

20 According to a particular embodiment, said compound is a nucleoside selected among the nucleosides adenosine, guanosine, cytidine, thymidine and mixtures thereof.

Preferably, said compound is cytidine at a concentration at least 1g/l, preferable at least 10 g/l, and most preferably at least 25 g/l.

Preferably, said compound is thymidine at a concentration at least 1g/l, preferable at least 10 g/l, and most preferably at least 25 g/l.

25 Yet more preferably, said compound is a mixture of cytidine and thymidine, each at a concentration of at least 1g/l, preferably of at least 10 g/l, and most preferably of at least 25 g/l.

30 It should be recognized, however, that these are only examples, convenient on the ground of availability, but that many other compounds able of undergoing specific base pairing interactions with nucleotides or nucleotide analogs can be constructed by someone skilled in the art, and enter in the frame of the invention.

In a specific embodiment, where the duplex is contacted with at least two different compounds able of undergoing specific base pairing interactions with nucleic acid, it is advantageous that these compounds cannot undergo mutually base pairing interactions, so that they remain fully available for base pairing interactions with the
5 nucleic acids or nucleic acid analogs to be tested.

For instance, the methods according to the invention with advantageously use cytidine and thymidine, or cytidine and adenosine, or guanosine and thymidine, or guanosine and adenosine, but not e.g. thymidine and adenosine, or cytidine and guanosine.

10 STRAND OF NUCLEIC ACIDS OR NUCLEIC ACID HOMOLOGS.

Strand of nucleic acids or nucleic acid homologs means single stranded RNA, DNA, LNA, PNA, or any artificial or natural analog of nucleic acids, capable of hybridizing with a natural single stranded RNA or DNA.

According to one embodiment, the methods according to the invention may be
15 used to determine whether there is a mismatch between molecules of (1) genomic DNA or mRNA isolated from a biologic sample and (2) a nucleic acid probe complementary to wild type DNA, when molecules (1) and (2) are hybridized to each other to form a duplex.

For example, the duplex may be issued from the hybridization of BRCA1 gene genomic DNA or BRCA1 mRNA isolated from a human biologic sample with a nucleic
20 acid probe complementary to human wild-type BRCA1 gene DNA.

Of course, within the field of the invention, the complementary strands can be in the composition as a paired or partly paired double helix.

In particular, and as a non restrictive example, in the context of the invention, "two homologous strands of nucleic acids or nucleic acids homologs" can designate a
25 heteroduplex pair, as encountered e.g. in EHDA but also an oligonucleotide attached to a solid support, hybridized at least in part with a DNA or RNA strand contained in a solution contacted to this solid support. The latter situation is particularly suitable for application of the invention to hybridization arrays.

These strands of nucleic acid, paired in a duplex form or not, are generally
30 issued from a nucleic acid sample.

Preferably, said nucleic acid sample contains a mixture of (+) strands and (-) strands.

When the initial nucleic acid sample contains a mixture of single stranded and double stranded nucleic acid molecules, the claimed method may comprise a preliminary and additional step of removing single stranded nucleic acid molecules.

When the initial nucleic acid sample contains mostly RNA, double stranded
5 cDNAs are first synthesized using any technique known to those skilled in the art. Then, cDNAs of interest derived from a single gene or a limited set of genes are selectively amplified from said double stranded cDNA sample. Preferentially, methods of amplification are used to obtain targeted polynucleotide samples. Any linear or logarithmic method of amplification may be used including the ligase chain reaction, the polymerase
10 chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA).

Similarly, when the initial polynucleotide sample contains mostly genomic DNA, the targeted DNA sample is preferably obtained by PCR.

The invention encompasses all biological samples containing nucleic acid(s)
15 without any particular limitation. More particularly, a biological sample according to the invention may originate from a cell, a tissue, an organ, a surgical or a biopsy specimen fixed or non-fixed such as bone marrow aspirates, or a biological fluid including body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears,
20 saliva, milk, white blood cells, and cell culture supernatants. The origin of the sample can be animal (preferably mammal, more preferably human), plant, virus, bacteria, protozoan or fungus. The sample may be eukaryotic, prokaryotic, or acellular. Cells comprised in the biological sample, especially when coming from a tissue, organ, biological fluid or biopsy, can be cultivated in order to increase the number of available cells. The sample may
25 contain cells from a single type or of mixed cell type. The cells, tissues and specimens may originate from normal individuals or from patient suffering from a disease or a disorder. The disease or disorder can be, for example, a cancer, a neurodegenerative disease, an inflammatory disease, a cardiovascular disease, an immune disorder, a body weight disorder such as obesity, etc. Any particular cell, cell type, pathological cell, cell at a
30 particular state of development or disease progression, are contemplated in the present invention.

Within the scope of the invention, we call "complementary in part" two DNA, RNA, or DNA analogs, which bear complementary sequences except for one or a few mutations affecting a small number of base pairs, such as single base substitution, single base insertion or deletion, or more generally substitutions, insertions or deletions affecting only a minor fraction of the length of said DNA, RNA, or DNA analogs.

MUTATION

The methods according to the invention are particularly advantageous for assaying point mutations.

The consequences of a point mutation may range from negligible to lethal, depending on the location and effect of the sequence change in relation to the genetic information encoded by the DNA, and it may often be at the origin of a disease or of a predisposition to a disease. The bases A and G are purines, while T and C are pyrimidines. Whereas the normal base pairings in DNA (A with T, G with C) involve one purine and one pyrimidine, the most common single base mutations involve substitution of one purine or pyrimidine for the other (e.g., A for G or C for T), a type of mutation referred to as a "transition". Mutations in which a purine is substituted for a pyrimidine, or vice versa, are less frequently occurring and are called "transversions". One may also encounter point mutations comprising the addition or loss of a single base arising in one strand of a DNA duplex at some stage of the replication process. Such mutations are called single base "insertions" or "deletions", respectively, and are also known as "frameshift" mutations, due to their effects on translation of the genetic code into proteins. Larger mutations affecting multiple base pairs also do occur and can be important in medical genetics. In particular, some mutations can arise due to "slippage" of the replication machinery in repeated DNA regions, leading to insertions or deletions of variable size.

According to the invention, detectable point mutations include deletion mutation, insertion mutation, and substitution mutation wherein an incorrect base pairing occurs.

If the difference between two homologous strands of nucleic acid paired in a duplex form consists in a single nucleotide difference or a small insertion or deletion a mismatched duplex is formed. The methods according to the invention are particularly efficient for detecting mismatched duplex.

More specifically, the methods according to the invention are particularly useful for the screening of a DNA fragment having a nucleic sequence related to a gene on which point mutation(s) has been associated or putatively associated with a disease or an increased predisposition to a disease. Said diseases can be different types of cancers, genetic diseases or increased predisposition to a disease such as, as an example, thalassemia, cardiovascular diseases, myopathy, cancer, and more generally genetically inheritable diseases. A non-exhaustive list of such diseases, with the associated genes, and prevalence in the population, is given in the following table as a matter of example. This list should not be considered by any means as limiting the scope of the invention, but is proposed here only to make it clear that the range of applications of the invention in human health is large and constantly expanding with the progress of genetics.

Non-limiting list of genes associated with increased predisposition to cancerous diseases, the diagnosis of which constitutes a privileged range of application of the invention.

Predisposition	Associated putative mutated gene(s)	Frequency of mutation bearers in general population	Frequency of mutation bearers in cancer affected patients
Breast, ovary	BRCA1, BRCA2	1/500	1/30
Colon, endometrium (HNPCC syndrome)	hMLH1, hMSH2, hMSH6, hPMS2, TGFbeta	1/500	1/20
Melanoma	CDKN2A, CDK4	1/500	1/20
Kidney	c-MET	1/5000~10000	1/20
Stomach (excluding HNPCC)	CDH1	1/10000~20000	1/100~200
Colon	APC	1/8000	1/100
Hamartomatoses			
VHL	VHL	1/40000	
NF2	NF2	1/30000	
Peutz-Jegherz	LKB1	1/50000~100000	
Gorlin syndrom	PTCH	1/50000~100000	
Cowden, Banayan-Zonana syndrom	PTEN	1/50000~100000	
NF1	NF1	1/3000	
Bourneville sclerosis	TSC1, TSC2	1/10000~15000	
Multiple endocrinian neoplasia			

Type 1	MEN1	1/30000~40000	
Type 2	Ret	1/30000~40000	1/10~20
Carney syndrom	PRKAR1A	1/50000~80000	
DNA breakage associated diseases			
Ataxia	ATM	1/40000~300000	
Telangiectasia			
Fanconi disease	6 associated genes	1/350000	
Bloom disease	BLM	1/1000000	
Xeroderma pigmentosum	8 associated genes	1/500000~1000000	
Werner disease	WRN	1/300000~1000000	

In particular, the methods according to the invention are particularly useful for the screening of the human breast cancer predisposing genes, (BRCA) like BRCA1 and
5 BRCA2, for mutations.

According to the methods of the present invention, alteration(s) of the wild type BRCA1 or BRCA2 locus may be detected. In addition, the methods can be performed by detecting the wild type BRCA1 or BRCA2 locus and thus confirming the lack of a predisposition to cancer at BRCA1 or BRCA2 locus.

10 As stated previously, the instant invention also relates to a composition including at least a DNA fragment having a nucleic sequence related to a gene on which point mutation(s) has been associated or putatively associated with a disease or an increased predisposition to a disease, and at least a compound able to undergo specific base pairing interaction at a concentration of at least 1 g, and as defined previously.

15 According to a specific embodiment, the nucleic sequence relates to human breast cancer predisposing genes (BRCA).

ANALYTIC METHODS

In one embodiment of the present invention, the analytical method is an
20 electrophoretic analysis, in particular using a liquid separating medium.

More particularly, the nucleic acid(s) having mismatch, in particular heteroduplex(es), are detected by capillary electrophoresis or electrophoresis in microchannels, in non-denaturing conditions.

The invention is particularly advantageous for capillary electrophoresis or electrophoresis in microchannels for the following reasons.

It improves significantly the sensitivity of electrophoretic analysis, especially for difficult to detect mismatches such as substitutions.

5 It allows for a much faster separation than sequencing.

It allows for multiplexing in different ways, thus increasing further the throughput.

10 In a preferred embodiment, multiplexing can be achieved by combining in the same run fragments with different lengths: since the homoduplex and heteroduplexes generally have close mobilities, several combinations of homoduplexes and heteroduplexes can be separated and identified in a single run, by mixing fragments with sufficiently different sizes. Typically, the fragments must differ in size by a factor between 10 and 100 bp, preferably between 20 and 100 bp.

15 In another preferred embodiment, which can be combined with the previous one, multiplexing can be performed e.g. by preparing different samples bearing tags with fluorescence at different wavelength, using e.g. PCR with different fluorescently labeled primers. The amplification of the different samples can be performed in a single reaction, and the mixture can be analysed in a single electrophoresis run. Several capillary electrophoresis machines, designed for DNA sequencing or fragment analysis, such as the
20 ABI 310, 3100, 3700, or the Amersham "Megabace", can analyse simultaneously products with different fluorescence emission wavelength.

Finally, multiplexing can also be achieved by performing several sequential injections of different samples. The principle is the same as for the separation of fragments of different sizes: it uses the fact that, in contrast with e.g. sequencing, electrophoretic
25 analysis of a single fragment only uses a very limited part of the separation window offered by electrophoresis, so that several samples, with start time suitable shifted, can be separated in a single run.

In another embodiment, the separation of the heteroduplex fragments can be performed by DGGE, in the presence of a composition as described in the invention, or by
30 DHPLC in the presence of the same type of composition.

The invention also concerns a composition including at least a compound able to undergo specific base pairing interaction at a concentration of at least 1g/l and as defined previously and a polymeric liquid medium for electrophoretic analysis.

According to a preferred embodiment, the electrophoretic method and the composition or kit, as defined previously, involve the use of a liquid separating medium as disclosed in WO 02/01218 (included here by reference). More specifically, this liquid separating medium contains at least one polymer composed of several polymer segments, said polymer being of the irregular block copolymer type or irregular comb polymer type and having on average at least three junction points established between polymer segments of different chemical or topological nature.

One particularly preferred embodiment consists in presenting within the copolymer according to the invention at least one type of polymer segment showing, within the separating medium, specific affinity for the solid support, and at least one type of polymer segment showing in said medium less or no affinity for the solid support.

The presence of polymer segments of this type allows the medium according to the invention to reduce the adsorption of species onto the walls of the channel and/or the electro-osmosis.

In a preferred embodiment, the polymeric medium used according to the invention contains at least a polymer at a concentration of at least 1%, in particular of at least 3% and more particularly of at least 4% by weight of its total weight. In another preferred embodiment, said polymer contains acrylamide or substituted acrylamide.

According to a specific embodiment, the polymer is a block copolymer(s) having an acrylamide backbone and polydimethylacrylamide (PDMA) side-chains.

The following are most particularly suitable for the invention:

- copolymers of the comb copolymer type, the skeleton of which is of dextran, acrylamide, acrylic acid, acryloylaminoethanol or (N,N)-dimethylacrylamide type and onto which are grafted side segments of acrylamide, substituted acrylamide or (N,N)-dimethylacrylamide (DMA) type, or of the DMA/allyl glycidyl ether (AGE) copolymer type, or alternatively of homopolymer or copolymer of oxazoline or of oxazoline derivatives;

- non-thermosensitive copolymers of the irregular sequential block copolymer type having along their skeleton an alternation of segments of polyoxyethylene

type and of segments of polyoxypropylene type, or an alternation of segments of polyoxyethylene type and of segments of polyoxybutylene type, or more generally an alternation of segments of polyethylene and of segments of polyether type that are appreciably more hydrophobic than polyoxyethylene;

5 - copolymers of the irregular sequential block copolymer type having along their skeleton an alternation of segments of acrylamide, acrylic acid, acryloylaminoethanol or dimethylacrylamide type, on the one hand, and segments of (N,N)-dimethylacrylamide (DMA) type, or of DMA/allyl glycidyl ether (AGE) copolymer type, or alternatively of homopolymer or copolymer of oxazoline or of oxazoline derivatives;

10 - polymers of the irregular comb polymer type, the skeleton of which is of agarose, acrylamide, substituted acrylamide, acrylic acid, acryloylaminoethanol, dimethylacrylamide (DMA), allyl glycidyl ether (AGE) polymer type, DMA/AGE random copolymer type, oxazoline and oxazoline derivative, dextran, methylcellulose, hydroxyethylcellulose, modified cellulose, polysaccharide or ether oxide type, and onto
15 which are grafted side segments of agarose, acrylamide, substituted acrylamide, acrylic acid, acryloylaminoethanol, dimethylacrylamide (DMA), allyl glycidyl ether (AGE) polymer type, DMA/AGE random copolymer type, oxazoline and oxazoline derivative, dextran, methylcellulose, hydroxyethylcellulose, modified cellulose, polysaccharide or ether oxide type;

20 - copolymers of the irregular comb copolymer type, the skeleton of which is of acrylamide, substituted acrylamide, acrylic acid, acryloylaminoethanol, dimethylacrylamide (DMA), allyl glycidyl ether (AGE) polymer type, DMA/AGE random copolymer type, oxazoline and oxazoline derivative, dextran, agarose, methylcellulose, of hydroxyethylcellulose, modified cellulose, polysaccharide or ether oxide type, and bears
25 short-chain hydrophobic side segments such as alkyl chains, aromatic derivatives, fluoroalkyls, silanes or fluorosilanes.

It should also be noted that, in most applications, it is preferable to use a polymer according to the invention that is essentially neutral. However, it may be useful for certain applications, and in particular to avoid the adsorption of species containing both
30 charges and hydrophobic portions, to select a polymer according to the invention that is deliberately charged, preferably opposite in charge to that of said species.

As regards the preparation of the copolymers used according to the invention, it may be carried out by any conventional polymerization or copolymerization technique.

5 In another specific embodiment, the analytical method is a hybridization type method.

Nucleic acids probe or nucleic acid homologs may be disposed on a surface as an array of domains, such system forming a hybridization array. The invention is interesting in this context, because it enhances the difference of stability between perfectly matched pairs, and pairs with a mismatch. This enhancement is particularly sensitive for
10 minor mismatches, such as those resulting from substitution, which are the most difficult mutation to detect in hybridization arrays.

In another specific embodiment, the nucleic acids probe or nucleic acid homologs may be disposed on the surface of particles or beads. By this way, the sample is contacted, in the presence of compounds as defined in the invention, with a multiplicity of
15 differently tagged beads, each probe being attached to an ensemble of beads or particles bearing a unique tag or combination of tags, as described e.g. in WO 99/37814. In this method, hybridization of a single sample to a multiplicity of probes can be performed in one batch, and the sequence of the hybridized targets can be identified uniquely by the tags or the beads they bind to.

20 More generally, the compounds considered according to the invention are advantageous to amplify the difference between nucleic acids presenting small sequence differences, in all methods for amplification or detection of nucleic acids, involving the annealing of a primer on the target nucleic acid, or the action of a polymerase on such target nucleic acid.

25 According to another embodiment, the invention proposes a method for assaying a nucleic acid for mutation comprising at least the steps consisting in:

- performing a polymerase chain reaction on said nucleic acid in the presence of at least two primers and a pool of compounds able to undergo specific base pairing interaction with nucleotides or analog thereof, said compounds being at a combined
30 concentration of at least 1 g/l and being unable to interfere with the polymerase chain reaction, and
- analyzing or quantifying the so-obtained DNA fragments.

Such a method is particularly interesting in the frame of quantitative or competitive PCR, or in the use of PCR since it is able to decrease the stability of primers on nucleic acids presenting a mismatch with the primer sequences, and thus to enhance the difference in amplification between perfectly matched and imperfectly matched amplification.

Thanks to its ability to increase the effect of mismatched base pair associated with mutations, the invention is also particularly suitable in conjunction with methods and compositions for detecting mutations using DNA probes called "molecular beacons", as described e.g. in Bonnet G, Tyagi S, Libchaber A, and Kramer FR (1999) "Thermodynamic basis of the enhanced specificity of structured DNA probes". Proc Natl Acad Sci USA 96, 6171-6176. Such DNA probes are single-standed DNA molecules that may form a stem-and-loop structure and possess an internally quenched fluorophore. They become fluorescent only when they bind to complementary nucleic acids.

In particular, molecular beacons are combinations of a first fluorescent molecule or group and a second molecule or group capable of transferring energy to said first fluorescent molecule or group, or of quenching fluorescent from said fluorescent molecule or group, and they have been used for detection of single-nucleotide variations, as described e.g. in Marras SAE, Kramer FR, and Tyagi S (1999) "Multiplex detection of single-nucleotide variations using molecular beacons". Genet Anal 14, 151-156.

Accordingly, the invention also proposes a composition including at least a compound able to undergo specific base pairing interaction as defined previously and at a concentration of at least 1g/l, and a pair of molecules or groups acting as a DNA probe called "molecular beacon".

The figures and examples given below are presented by way of non limiting illustration of the present invention.

FIGURES

Figure 1: Electropherogram representing the separation of different fragments of human genes BRCA1 and BRCA2, having respectively a different point mutation, and represented in sequence SEQ ID NO 4, SEQ ID NO 5 and SEQ ID NO 6, in presence or in absence of thymidine (see Example 1).

Figure 2: Electrophoregram representing a separation identical to that of Figure 1 involving fragments of human genes BRCA2 and BRCA1 represented in sequence SEQ ID NO 2 and SEQ ID NO 6, in presence or in absence of cytidine (see Example 2).

5 Figure 3: Comparison of the resolution between electrophoregram representing a separation of fragments of human genes BRCA2 represented in sequence SEQ ID NO 2, in presence or in absence of different compounds able to undergo specific base pairing interaction of the present invention (see Example 3).

Figure 4: Electrophoregram representing a separation close to that of Figure 1 in presence of different concentrations of cytidine (see Example 4).

10 Figure 5: Control electrophoregram representing a separation of fragments of human genes BRCA1 and BRCA2 represented in sequence SEQ ID NO 3 and in SEQ ID NO 1, in presence or in absence of urea (see Example 5).

15 Figure 6: Electrophoregram representing the separation of fragments of human genes BRCA1 represented in sequence SEQ ID NO 6, in presence or in absence of thymidine 2,5 % and cytidine 2,5 % (see Example 6).

EXAMPLES

All fragments used for separations are issued from human genes BRCA1 and BRCA2.

20 The sequence of the genes, the primers used for amplifying the fragments are listed in table 1. Concerning the mutations termed SEQ ID NO 4 and SEQ ID NO 5 the concerned point mutation is respectively located at the eightieth and fifth place from the closest end of considered gene.

25 Type of substitution, fragment size, sequence (primer regions are underlined), exon and gene are shown in the following table. The point of mutation is shown in black type.

The copolymers of liquid separating medium were prepared according to the process of preparation disclosed in WO 02/01218.

30

TABLE 1

Gene	Exon	Nucleotide position (cDNA)	Identification	Type	amplicon size (bp)	sequence	annealing °C
BRCA2	22	9058	SEQ ID NO 1 (2383)	A/T	311	<p> <u>GTTCGTGATTGCTTTTATTC</u>CAATATCTTA AATGGTCACAGGGTTATTTTCAGTGAAGA GCAGTTAAGAGCCTTGAATAATCACAGG CAAATGTTGAATGATAAGAAACAAGCTC AG A TCCAGTTGGAAATTAGGAAGGCCA TGGAAATCTGCTGAACAAAAGGAACAAGG TTTATCAAGGGATGTCACAACCGTGTGG AAGTTGCGTATTGTAAGCTATCAAAAA AAGAAAAAGATTTCAGGTAAGTATGTAAA TGCITTTGTTTTATCAGTTTTTAACTTA AAAAAATGACCTTACTAACAAAATGATTA </p>	58
BRCA2	3	451	SEQ ID NO 2 (2501)	G/C	319	<p> CACTGGTTAAAACTAAGGTGGGATTTT TTTAAATAGATTTAGGACCAATAAGCTT AATTGGTTTGAAGAACTTCTTCAGAAGC TCCACCTATAATTCTGAACCTGCAGAA GAATCTGAACAATAAAAAACAACAAATTACG AACCAAACTATTTAAAACTCCACAAAG GAAACCATCTTATAATCAGCTG G CTTC AACTCCAATAATATTCAAAGAGCAAGGG CTGACCTGCGCTGTACCAATCTCCTGT AAAAGAATAGATAAATTCAAATTAGACT TAGGTAAGTAATGCAATATGGTAGACTG <u>GGGAGAAC</u> </p>	65
BRCA1	15	4719	SEQ ID NO 3 (1019)	G/A	251	<p> <u>TGGCGATGGTTTCTCCCTCCATTTATCTT</u> TCTAGGTCATCCCTTCTAAATGCCCATC ATTAGATGATAGGTGGTACATGCACAGT TGCTCTGGGAGTCTTCAGAATAGAACT ACCCATCTCAAGAGGAGCTCATTAAGGT TGTGAT G TGGAGGAGCAACAGCTGGA AGAGTCTGGGCCACACGATTTCACGGAA ACATCTTACTTGCCAAGGCAAGATCTAG <u>GTAATATTTTCATCTGCTGTATTTGGA</u> </p>	50
BRCA1	15	4719	SEQ ID NO 4 (1019_80)	G/A	251	<p> <u>CTGGTACATGCCACAGTTGCTCTGGGAGT</u> CTTCAAGATAGAACTACCCATCTCAAG AGGAGCTCATTAAGGTTGTTGAT G TGG AGGAGCAACAGCTGGAAGAGTCTGGGCC ACACGATTTGACGGAAACATCTTACTTG CCAAGGCAAGATCTAGGTAATATTTTCAT CTGCTGTATTGGAACAAACACTTTGATT TACTCTGAATCCTACATAAAGATATTCTG <u>GTTAACCAACTTTTAGATGTACTAGTC</u> </p>	56
BRCA1	15	4719	SEQ ID NO 5 (1019_50)	G/A	251	<p> <u>CTTCAGAATAGAACTACCCATCTCAAG</u> AGGAGCTCATTAAGGTTGTTGAT G TGG AGGAGCAACAGCTGGAAGAGTCTGGGCC ACACGATTTGACGGAAACAICTTACTTG CCAAGGCAAGATCTAGGTAATATTTTCAT CTGCTGTATTGGAACAAACACTTTGATT TACTCTGAATCCTACATAAAGATATTCTG <u>GTTAACCAACTTTTAGATGTACTAGTCTA</u> <u>TATGGACACTTTTGTATATAC</u> </p>	56
BRCA1	11(01)	855	SEQ ID NO 6 (2542)	T/G	205	<p> <u>TGTATTTTTTAATGACAATTCAGTTTTT</u> GAGTACCTTGTTATTTTGTATATTTTCA GCTGCTTGGAATTTTCTGAGACGGATGT AACAAATACTGAACATCATCAACCCAGT AATAATGAT T TGAACACCACTGAGAAG CGTGCACTGAGAGGCATCCAGAAAAGT <u>ATCAGGGTAGTTCTGTTTCAAACTTGCA</u> <u>TGTGGAG</u> </p>	55

EXAMPLE 1

Comparison of the detection of different substitutions between:

- P(AM-PDMA)18 at 5g/100 mL + sybrgreen 1X (Molecular Probes) in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer, and

5 - P(AM-PDMA)18 at 5 g/100 mL + thymidine at 2,5 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer.

10 - PDMA side-chains with initiator-monomer ratio $R_0=0,015$ and $A_0=0,01$ where $R_0 = [R-SH]/[PDMA]$ and $A_0 = [KPS]/[PDMA]$ and P(AM-PDMA)18 were prepared according to the protocols presented in V. Barbier, B.A. Buchholz, A.E. Barron, J.L. Viovy, Electrophoresis, 23, 1441, (2002)) with $[(NH_4)_2S_2O_8]/[AM] = 0,1 \%$ and $[Na_2S_2O_5]/[AM] = 0,015 \%$.

15 Separations were made in a ABI 310 (applied biosystem) at 30°C. Bare fused silica capillary (polymicro), 50 μm inner diameter, 61 cm long (50 cm to the detection window) were used. Injection is electrokinetic (2,5 kV during 30s). Pre-electrophoresis is done at 12,2 KV during 5 minutes. Separation is done at 12,2 kV. After each run, new polymer solution is pushed into the capillary during 10 minutes.

20 Samples were prepared by gently mixing 2 μL PCR product with 5 μL pure water (milliQ). Point mutation of SEQ ID NO 4 (Substitution 1019_80), SEQ ID NO 5 (1019_50) and SEQ ID NO 6 (2542) were studied. We can clearly observe that resolution is improved with the use of thymidine (Figure 1.B. and 1.C) and that SEQ ID NO 5 (substitution 1019_50) which was not detected with P(AM-PDMA)18 5 g/100 mL is detected with P(AM-PDMA)18 5 g/100 mL + thymidine 2,5 g/100 mL (Figure 1.A). For each substitution a sample from a heterozygote patient was compared to one of a homozygote. The data clearly demonstrate that the addition of thymidine, at concentrations

25 of 2,5 g/100 ml, increase the resolution between homozygote and heterozygote DNA, and provide a clear detection of the presence of the mutation (multiple peak for the heterozygote electrophoregram).

EXAMPLE 2

30 Comparison of the detection of different substitutions between:

- P(AM-PDMA)20 at 5g/100 mL + sybrgreen 1X (Molecular Probes) in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer, and

- P(AM-PDMA)20 at 5 g/100 mL + cytidine at 2,5 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer.

PDMA side-chains with $R0 = 0,015$ and $A0 = 0,01$ and P(AM-PDMA)20 were prepared according to the protocols presented in (V. Barbier, B.A. Buchholz, A.E. Barron, J.L. Viovy, Electrophoresis, 23, 1441, (2002)) with $[(NH_4)_2S_2O_8]/[AM] = 0,1 \%$ and $[Na_2S_2O_5]/[AM] = 0,015 \%$.

Separations were made in a ABI 310 (applied biosystem) at 30 °C. Bare fused silica capillary (polymicro), 50 µm inner diameter, 61 cm long (50 cm to the detection window) were used. Injection is electrokinetic (2,5 kV during 30s). Pre-electrophoresis is done at 12,2 KV during 5 minutes. Separation is done at 12,2 kV. After each run, new polymer solution is pushed into the capillary during 10 minutes.

Samples were prepared by gently mixing 2 µL PCR product with 5 µL pure water (milliQ). Point mutation of SEQ ID NO 2 (Substitution 2501) and SEQ ID NO 6 (2542) were studied. Mutation of SEQ ID NO 2 (Substitution 2501) which was not detected with P(AM-PDMA)20 5 g/100 mL is detected with P(AM-PDMA)20 5 g/100 mL + cytidine 2,5 g/100 mL (Figure 2.A) and resolution of mutation of SEQ ID NO 6 (substitution 2542) was improved by using P(AM-PDMA)20 5 g/100 mL + cytidine 2,5 g/100 mL compared to P(AM-PDMA)20 5 g/100 mL (Figure 2.B). For each substitution a sample from a heterozygote patient is compared to one of a homozygote. The data clearly demonstrate that the addition of cytidine, at concentrations of 2.5 g/100 mL, increase the resolution between homozygote and heterozygote DNA, and provide a clear detection of the presence of the mutation (multiple peak for the heterozygote electrophoregram).

25 EXAMPLE 3

Comparison of the detection of different substitutions between:

- P(AM-PDMA)20 at 5g/100 mL + sybrgreen 1X (Molecular Probes) in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer,
- P(AM-PDMA)20 at 5 g/100 mL + thymidine at 5 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer,
- P(AM-PDMA)20 at 5 g/100 mL + cytidine at 5 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer,

And:

- P(AM-PDMA)20 at 5 g/100 mL + thymidine at 2,5 g/100 mL + cytidine at 2,5 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer.

5 Separations were made in a ABI 310 (applied biosystem) at 30°C. Bare fused silica capillary (polymicro), 50 µm inner diameter, 61 cm long (50 cm to the detection window) were used. Injection is electrokinetic (2,5 kV during 30s). Pre-electrophoresis is done at 12,2 KV during 5 minutes. Separation is done at 12,2 kV. After each run, new polymer solution is pushed into the capillary during 10 minutes.

10 Samples were prepared by gently mixing 2 µL PCR product with 5 µL pure water (milliQ). Point mutation of SEQ ID NO 2 (Substitution 2501) was studied. This substitution is not detected with P(AM-PDMA)20 at 5 g/100 mL (only one peak). It is detected with P(AM-PDMA)20 at 5 g/100 mL + cytidine 2,5 g/100 mL and P(AM-PDMA)20 at 5 g/100 mL + thymidine 2,5 g/100 mL (two peaks) and resolution is
15 improved with P(AM-PDMA)20 at 5 g/100 mL + cytidine 2,5 g/100 mL + thymidine 2,5 g/100 mL (three peaks) (Figure 3). For each substitution a sample from a heterozygote patient is compared to one of a homozygote. At equal concentration of nucleoside, resolution is better for the case with an equal mix of cytidine and thymidine, than with either cytidine alone, or thymidine alone. This demonstrates the synergistic effect of
20 having in the separation medium two different additive compounds, able of achieving base pairing interactions with different nucleotides.

EXAMPLE 4

Comparison of the detection of different substitutions between:

- 25 - P(AM-PDMA)20 at 5g/100 mL + cytidine at 0,05 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer,
- P(AM-PDMA)20 at 5 g/100 mL + cytidine at 1 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer,
- P(AM-PDMA)20 at 5 g/100 mL + cytidine at 2,5 g/100 mL + sybrgreen
30 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer.

Separations were made in a ABI 310 (applied biosystem) at 30°C. Bare fused silica capillary (polymicro), 50 µm inner diameter, 61 cm long (50 cm to the detection window) were used. Injection is electrokinetic (2,5 kV during 30s). Pre-electrophoresis is done at 12,2 KV during 5 minutes. Separation is done at 12,2 kV. After each run, new polymer solution is pushed into the capillary during 10 minutes.

Samples were prepared by gently mixing 2 µL PCR product with 5 µL pure water (milliQ). Point mutation of SEQ ID NO 5 (Substitutions 1019_50) and SEQ ID NO 6 (1019_80) were studied. Both are not detected with a cytidine concentration inferior or equal to 1 g/100 mL (only one peak) and are detected with cytidine concentration of 2,5 g/100 mL (two peaks) (Figure 4 A and B).

EXAMPLE 5

Comparison of the detection of different substitutions between:

- P(AM-PDMA)5 at 5g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer,
- P(AM-PDMA)5 at 5 g/100 mL + urea at 15 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer,
- P(AM-PDMA)5 at 5 g/100 mL + urea at 24 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer.

Separations were made in a ABI 310 (applied biosystem) at 30°C. Bare fused silica capillary (polymicro), 50 µm inner diameter, 61 cm long (50 cm to the detection window) were used. Injection is electrokinetic (2,5 kV during 30s). Pre-electrophoresis is done at 12,2 KV during 5 minutes. Separation is done at 12,2 kV. After each run, new polymer solution is pushed into the capillary during 10 minutes.

Samples were prepared by gently mixing 2 µL PCR product with 5 µL pure water (milliQ). Point mutation of SEQ ID NO 3 (Substitutions 1019) and SEQ ID NO 1 (2383) were studied. Both are detected when no urea is added to the matrix and not detected when urea concentration in the matrix is 15 g/100 mL. When urea concentration in the matrix is 24 g/100 mL, mutation of SEQ ID NO 1 (2383) is still not detected and SEQ ID NO 5 (1019) is detected with a lower resolution as in the case without urea (Figure 5). This demonstrates that additives known to favor duplex DNA denaturation but not able

to lead to base pairing interactions with nucleic acids, such as urea, proposed for the resolution of mutation in the prior art, actually has an effect on the resolution of heteroduplexes which is deleterious, and opposite to this of additives of the invention.

5

EXAMPLE 6

Comparison of the detection of point mutation of SEQ ID NO 6 (substitution 2542) between :

- Linear polyacrylamide at 5g/100 mL + sybrgreen 1X (Molecular Probes) in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer, and
- 10 - Linear polyacrylamide at 5 g/100 mL + thymidine at 2,5 g/100 mL + cytidine at 2,5 g/100 mL + sybrgreen 1X in Tris (50 mM) Taps (50 mM) EDTA (2 mM) buffer.

Separations were made in a ABI 310 (applied biosystem) at 30°C. Bare fused
15 silica capillary (polymicro), 50 µm inner diameter, 61 cm long (50 cm to the detection window) was coated according the protocol presented in Chiari M, Cretich M, Horvath J. *Electrophoresis*, 2000, 21, 1521-1526, before use. Injection is electrokinetic (2,5 kV during 30s). Pre-electrophoresis is done at 12,2 KV during 5 minutes. Separation is done at 12,2 kV. After each run, new polymer solution is pushed into the capillary during 10
20 minutes.

Samples were prepared by gently mixing 2 µL PCR product with 5 µL pure water (milliQ). The figure 6 shows clearly observe that resolution is improved with the use of nucleosides. A sample from a heterozygote patient was compared to one of a homozygote.

25

CLAIMS

1. A method for assaying the presence or the absence of at least one mutation on a strand of nucleic acids paired in a duplex form comprising at least the steps consisting of:

- contacting in a liquid medium said duplex, suspected to include at least one mismatch with at least one compound able to undergo a specific base pairing interaction with said mismatch, said compound being at a concentration of at least 1g/l in said medium and,

- assaying for said mismatch by an analytical method.

2. The method according to claim 1, wherein the strands of nucleic acids paired in duplex form are two DNA strands which are in all or in part complementary.

3. A method for performing Electrophoretic Heteroduplex Analysis "EHDA" on a nucleic acid sample suspected to include at least one heteroduplex, said method comprising at least the steps consisting of:

- contacting in a liquid medium said nucleic acid sample suspected to include at least one heteroduplex, with at least one compound able to undergo a specific base pairing interaction with at least one mismatch of said heteroduplex, said compound being at a concentration of at least 1g/l of said medium,

- assaying for the presence of said heteroduplex thanks to its electrophoretic mobility.

4. The method according to claim 3 comprising a preliminary step of denaturing the nucleic acid sample and renaturing it in conditions convenient to achieve both heteroduplexes and homoduplexes.

5. A method for assaying the presence or the absence of at least one mutation on a single strand of nucleic acid in a liquid medium comprising at least the steps consisting of:

- (a) contacting said nucleic acid suspected to include at least one mutation with a nucleic acid probe grafted on a solid support,

- (b) allowing the hybridization of at least part of said strand of nucleic acid with the grafted nucleic acid probe,

- (c) washing non-hybridized strands, and

(d) assaying for said mutation by an analytical method, wherein the steps a) and/or c) are performed in the presence of at least one compound able to undergo a specific base pairing interaction with said mutation, said compound being at a concentration of at least 1g/l.

6. The method according to claims 1 to 5 wherein the strand(s) of nucleic acids is a single stranded DNA, RNA, LNA, PNA, or any artificial or natural analog of nucleic acids.

7. The method according to any one of claims 1 to 6, wherein the compound able to undergo a specific base pairing interaction includes at least two groups suitable for hydrogen bonding, in an orientation, polarity and spacing compatible with the creation of attractive interaction with at least one of the bases A, T, G, C and U.

8. The method according to any one of claims 1 to 7, wherein said compound is unable to interfere with polymerisation reactions of nucleotides and/or to be incorporated into a newly polymerized DNA strand.

9. The method according to any one of claims 1 to 8, wherein said compound is one oligonucleotide having a length of less than 5 nucleotides, a nucleoside, a base or a mixture thereof.

10. The method according to claim 9, wherein the oligonucleotide has a length of less than 3 nucleotides and preferably less than 2 nucleotides.

11. The method according to claim 9 or 10, wherein the compound is adenosine, guanosine, uridine, cytidine, thymidine, or mixtures thereof.

12. The method according to claim 9, 10 or 11, wherein oligonucleotide(s) or nucleoside(s) in the mixture of oligonucleotides or nucleosides are unable to undergo mutually base pairing interaction.

13. The method according to claim 12, wherein the compound includes cytidine and thymidine or cytidine and adenosine or guanosine and thymidine or guanosine and adenosine.

14. The method according to any one of the claims 1 to 13, wherein the compound(s) is used at a concentration of at least 10 g/l and preferably at least 25 g/l.

15. The method according to any one of the claims 1 to 14, wherein the mutation to assay is a point mutation.

16. The method according to any one of the claims 1 or 2 and 5 to 15, wherein said mutation is assayed by hybridization assay.

17. The method according to any one of the claims 1 to 4 or 6 to 15, wherein said mutation is assayed by an electrophoretic analysis using a liquid separating medium.

18. The method according to claim 17, wherein said liquid separation medium contains a polymer at a concentration of at least 1%, and preferably at least 3% by weight of the total weight of said medium.

19. The method according to claim 18, wherein the liquid separating medium contains at least one polymer composed of several polymer segments, said polymer being of the irregular block copolymer type or irregular comb polymer type and having on average at least three junction points established between polymer segments of different chemical or topological nature.

20. The method according to claim 19, wherein the polymer comprises at least one type of polymer segment showing, within the separating medium, specific affinity for the channel wall, and at least one type of polymer segment showing in said medium less or no affinity for the wall.

21. The method according to claim 19 or 20, wherein said polymer contains acrylamide or substituted acrylamides.

22. Use of a method according to any one of the claims 1 to 21 for diagnosing a predisposition to genetic diseases or cancers associated or putatively associated to specific point mutation(s) or the diagnosis or prognosis of said diseases or cancers.

23. Use according to claim 22, wherein said disease is associated to at least a point mutation in a human breast cancer predisposition gene (BRCA).

24. A composition including at least a compound able to undergo specific base pairing interaction at a concentration of at least 1g/l and a polymer, wherein the compound is as defined in any one of the claims 7 to 14 and the polymer is as defined in anyone of the claims 19 to 21.

25. A composition including at least a DNA fragment having a nucleic sequence related to a gene on which point mutation(s) has been associated or putatively associated with a disease or an increased predisposition to a disease, and at least a compound able to undergo specific base pairing interaction at a concentration of at least 1g/l, wherein said compound is as defined in anyone of the claims 7 to 14.

26. A composition including at least a compound able to undergo specific base pairing interaction at a concentration of at least 1g/l, and a pair of molecules or groups acting as a DNA probe called "molecular beacon", wherein said compound is as defined in any one of the claims 7 to 14.

27. A kit useful for the screening of a nucleic acid or analog thereof having a sequence related to a gene on which point mutation(s) has been associated or putatively associated with a disease or an increased predisposition to a disease, said kit comprising at least a composition according to claim 24.

28. A method for assaying a nucleic acid for mutation comprising at least the steps consisting in:

- performing a polymerase chain reaction on said nucleic acid in the presence of at least two primers and a pool of compounds able to undergo specific base pairing interaction with nucleotides or analogue thereof, said compounds being at a combined concentration of at least 1 g/l and being unable to interfere with the polymerase chain reaction and,



- analyzing and/or quantifying the so-obtained DNA fragments.

29. The method according to claim 28, wherein the compound is as defined in any one of the claims 7 to 14.


PCT/IB 03 / 06016

ABSTRACT



The present invention relates to a method for assaying the presence or the absence of at least one mutation on a strand of nucleic acid paired in a duplex form comprising at least the steps of contacting said duplex with at least one compound able to undergo a specific base pairing interaction with suspected mismatch and assaying for said mismatch by an analytical method. The invention further relates to the use in the diagnosis of predisposition to genetic diseases and cancers and in the diagnosis and prognosis of said diseases and cancers, like human breast cancer. The invention also relates to compositions including a compound able to undergo specific base pairing interaction, in association with a DNA fragment having a nucleic sequence relating to a gene on which point mutation(s) has been associated or putatively associated with a genetic disease or an increased predisposition to said disease.

FIGURE 1A**Substitution 1019_50****FIGURE 1B****Substitution 1019_80**

2/7

FIGURE 1C**Substitution 2542**

3/7

FIGURE 2A**Substitution 2501****FIGURE 2B****Substitution 2542**

4/7

FIGURE 3






FIGURE 4A**FIGURE 4B**

6/7

FIGURE 5




FIGURE 6**Substitution 2542**